Fig. 6.

Ex vivo incubation of L-4F to plasma from CHD subjects. Predose plasma samples from day 2 of the SC study were randomly chosen from 20 subjects in the study. Each plasma sample was incubated in vitro for 15 min at 37°C with 1,000 ng/ml of scrambled L-4F (Scr-L-4F) or 150 ng/ml, 375 ng/ml or 1,000 ng/ml of the L-4F peptide that was used in the clinical studies described here (Current) or L-4F peptide that had been used in previously published preclinical studies (13, 14; Previous). The plasma samples were then separated by fast-protein liquid chromatography (FPLC), and the HDL fractions were added to cultures of human aortic endothelial cells to determine the HII, as described in Materials and Methods. The data shown are mean ± SD. There was no difference in HII between the two sources of peptides. A similar dose-dependent improvement (decrease) in HII was observed after ex vivo addition of both peptides.